Prosecution Insights
Last updated: November 04, 2026
Application No. 18/510,293

ACARICIDE HETERODISSEMINATION BY SMALL MAMMALS

Final Rejection §103
Filed
Nov 15, 2023
Priority
Nov 15, 2022 — provisional 63/383,825
Examiner
KIM, DANIELLE A
Art Unit
1613
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Banfieldbio Inc.
OA Round
2 (Final)
36%
Grant Probability
At Risk
3-4
OA Rounds
6m
Est. Remaining
88%
With Interview

Examiner Intelligence

Grants only 36% of cases
36%
Career Allowance Rate
37 granted / 102 resolved
-23.7% vs TC avg
Strong +52% interview lift
Without
With
+52.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
75 currently pending
Career history
187
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
68.4%
+28.4% vs TC avg
§102
6.2%
-33.8% vs TC avg
§112
17.5%
-22.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 102 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority The instant application was filed 15 November 2023 and the Applicant claims priority to provisional application 63/383,825 filed 15 November 2022. Therefore, the effective filing date of the instant application is 15 November 2022. Examiner’s Note The Applicant's amendments and arguments filed 03 September 2026 are acknowledged and have been fully considered. The Examiner has re-weighed all the evidence of record. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. In the Applicant’s response, filed 03 September 2026, it is noted that claims 11-14 have been amended and no new claims have been canceled. Support for the amendments can be found in para. 8 of the specification. No new matter has been added. Claim Objections Claims 12 and 13 are objected to because of the following informalities: Claims 12 and 13 are dependent from claim 13. Appropriate correction is required. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 11-14 is/are rejected under 35 U.S.C. 103 as being unpatentable over Maupin et al. (US 6849266 B2) in view of Rheaume et al. (EP 0250908 A2). Regarding claim 11, Maupin teaches a device for controlling ectoparasites on small rodents (abs; entire teaching). The apparatus comprises an enclosure which is an opening to allow entry and exit of rodents. The device includes an applicator with an ectoparasiticide (col. 3, lns. 49-60). Acaricide in the instant claims is interpreted as a type of ectoparasiticide (substance to kill ticks and mites). The enclosure may include bait to lure the rodents (col. 8, lns. 37-53). Regarding the amendment in claim 11, the limitation of “wherein the electrostatically charged microspheres are configured to be passively acquired by small mammals bearing an electric charge of the opposite polarity as the microspheres without said mammal making direct contact with an applicator within the station” is interpreted as a product-by-process limitation. The limitation is describing the process instead of the final product/device. The limitation is therefore interpreted as comprising “electrostatically charged microspheres.” "[E]ven though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process." In re Thorpe, 777 F.2d 695, 698, 227 USPQ 964, 966 (Fed. Cir. 1985). Regarding claim 12, the opening of the device that allows for entry and egress of rodents is interpreted as excluding larger animals. Regarding claim 13, parts of the enclosure of the device is made of plastic (col. 8, lns. 54-58), which is simultaneously interpreted as reusable. Regarding claim 14, the ectoparasiticide in the enclosure may be applied using a fibrous material, such as strands of cotton wick (col. 8, ln. 66-col. 9, ln. 6), which is interpreted as a biodegradable material. Maupin does not specifically teach electrostatically charged microspheres that are encapsulated with entomopathogenic acaricides in claim 11. Rheaume teaches insecticides, such as microorganisms, bacteria, fungi, and viruses that are toxic to insects (pg. 4, lns. 30-34), such as mites (pg. 4, ln. 21), which is interpreted as an entomopathogenic acaricide in claim 11. The composition includes insecticides or pesticides that are entrapped by a charged polymer (pg. 2, lns. 27-28), where charged polymer is interpreted as “electrostatically charged” in claim 11. Rheaume provides an example of a bacteria that kills insects entrapped within a microsphere (Example 8), which is interpreted as an encapsulated microsphere comprising an electrostatically charged polymer and an entomopathogenic acaricide in claim 11. The composition can be applied to the pests or to the pests’ habitat (claims 15 and 16). Since Maupin does not specifically teach electrostatically charged microspheres that are encapsulated with entomopathogenic acaricides in claim 11, one of ordinary skill in the art would have been motivated to use Rheaume’s teaching with a reasonable expectation of success. A skilled artisan would have recognized the additional benefit of using an entrapped or encapsulated entomopathogenic acaricide for increased persistence and stability of the pesticides (Rheaume; pg. 2, lns. 22-23) in Maupin’s composition, which also prioritizes long-lasting and stable compositions (Maupin; col. 5, lns. 36-40). Furthermore, Rheaume’s teaching of using an entrapped or encapsulated entomopathogenic acaricide in a charged polymer with Maupin’s composition would result in a contactless device wherein based on the properties of ionic forces, the charged polymer will necessarily be able to transfer to an oppositely charged surface. Generally, it is prima facie obvious to select a known material for incorporation into a composition, based on its recognized suitability for its intended use (see MPEP § 2144.07). Response to Arguments Applicant's arguments filed 03 September 2026 have been fully considered but they are not persuasive. The Applicant argues that Maupin and Rheaume do not recite or suggest the language of independent claim 11 and the amendments (Remarks, pg. 10). Applicant’s argument is not found persuasive. Regarding the amendment in claim 11, the limitation of “wherein the electrostatically charged microspheres are configured to be passively acquired by small mammals bearing an electric charge of the opposite polarity as the microspheres without said mammal making direct contact with an applicator within the station” is interpreted as a product-by-process limitation. The limitation is describing the process instead of the final product/device. The limitation is therefore interpreted as comprising “electrostatically charged microspheres.” "[E]ven though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process." In re Thorpe, 777 F.2d 695, 698, 227 USPQ 964, 966 (Fed. Cir. 1985). The Applicant argues that the teachings call for an applicator, which is not required in independent claim 11 (Remarks, pg. 11). Applicant’s argument is not found persuasive. Rheaume’s teaching of using an entrapped or encapsulated entomopathogenic acaricide in a charged polymer with Maupin’s composition would result in a contactless device wherein based on the properties of ionic forces, the charged polymer will necessarily be able to transfer to an oppositely charged surface. The Applicant argues that Rheaue teaches using a molecular charge to entrap an active ingredient, whereas the present invention utilizes statistically-charged carriers (Remarks, pg. 11). Applicant’s argument is not found persuasive. Absent of a clear definition of “electrostatically charged microspheres” from the Applicant’s disclosure, as recited in instant claim 11, the limitation is given its broadest reasonable interpretation using customary and ordinary meaning. Therefore, the limitation is interpreted as a microsphere with an electrical charge. The composition in Rheaume’s teaching includes insecticides or pesticides that are entrapped by a charged polymer (pg. 2, lns. 27-28), where charged polymer is interpreted as “electrostatically charged” in claim 11. Rheaume provides an example of a bacteria that kills insects entrapped within a microsphere (Example 8), which is interpreted as an encapsulated microsphere comprising an electrostatically charged polymer and an entomopathogenic acaricide in claim 11. The Applicant argues that dependent claims 12-14 are patentable (Remarks, pg. 12). Applicant’s argument is not found persuasive. Regarding claim 12, the opening of the device that allows for entry and egress of rodents is interpreted as excluding larger animals. Regarding claim 13, parts of the enclosure of the device is made of plastic (col. 8, lns. 54-58), which is simultaneously interpreted as reusable. Regarding claim 14, the ectoparasiticide in the enclosure may be applied using a fibrous material, such as strands of cotton wick (col. 8, ln. 66-col. 9, ln. 6), which is interpreted as a biodegradable material. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Danielle Kim whose telephone number is (571)272-2035. The examiner can normally be reached M-F: 9-5 p.m. PST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Brian-Yong Kwon can be reached at (571)272-0581. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /D.A.K./Examiner, Art Unit 1613 /ANDREW S ROSENTHAL/Primary Examiner, Art Unit 1613
Read full office action

Prosecution Timeline

Nov 15, 2023
Application Filed
Mar 03, 2026
Non-Final Rejection mailed — §103
Sep 03, 2026
Response Filed
Oct 28, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778903
PHARMACEUTICAL COMPOSITION AND BREXPIPRAZOLE ORALLY SOLUABLE FILM
2y 10m to grant Granted Nov 03, 2026
Patent 12758485
INSTANT EFFECT EYE CREAM
4y 11m to grant Granted Oct 13, 2026
Patent 12734193
AMMONIUM CHLORIDE FORMULATION TO SUPPORT HUMAN NATURAL DEFENSE AGAINST VIRUSES
4y 9m to grant Granted Sep 15, 2026
Patent 12728081
SUNSCREEN FORMULATION
2y 7m to grant Granted Sep 08, 2026
Patent 12714671
CELL MEMBRANE LIPID-EXTRACTED NANOPARTICLES (CLENS) FOR SELECTIVE TARGETING, IMAGE ANALYSIS AND CANCER THERAPY
5y 7m to grant Granted Aug 25, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
36%
Grant Probability
88%
With Interview (+52.1%)
3y 6m (~6m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 102 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month